Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Update

25 Jan 2006 07:01

Plant Health Care PLC25 January 2006 Embargoed until 07.00 25 January 2006 Plant Health Care plc POST YEAR-END TRADING AND PRODUCT UPDATE Major support for Pre-Tect Product Increasing Interest for Myconate Trading Plant Health Care plc ("PHC" or the "Company"), a leading provider of naturalplant fertility products, is pleased to announce that since the update providedin its interim statement on 19 September 2005, it has continued to make goodprogress. Although some supplier delays have resulted in sales for the yearended 31 December 2005 being slightly below earlier expectations, better grossmargins and cost containment have been achieved which it believes will enablethe Company to report in line with expectations, before exceptional items, aspreviously referred to. The current year has started well, with the John Deere contract now wellunderway and indications that a number of new agreements will providesignificant revenue growth in Europe. The Company has, however, already begun toinvest in additional people, mainly in sales, to manage this growth and to moveforward some other initiatives, including Pre-Tect and Myconate testing. Major support for Pre-Tect Product The Company is pleased to announce very encouraging results followingindependent trials of its newly formulated, naturally derived Pre-Tect product.The tests were carried out in the UK on lettuce and spinach crops by several ofthe UK's largest salad growing companies and took place in several areas withdiverse climate and soil conditions. The tests were full farm replicated trialson whole head and cut leaf salads. Pre-Tect consistently increased the shelflife of the crops by 25% to 40% (3-5 days). Based on these trials, PHC hasentered into supply agreements with several of the largest European saladgrowers. Additionally, one of the largest supermarket chains in the UK isspecifying the use of Pre-Tect on all its salad crop purchases. Increasing Interest for Myconate PHC reported on the early results of its Myconate testing on 15 December 2005and still has tests ongoing with some of the world's largest agro chemical andseed companies. Mainly as a result of the trials that have already beencompleted in France, the largest corn growing country in Europe, a number ofmajor seed companies have expressed interest in expanding trials in 2006 andhave made initial enquiries about entering into distribution agreements. The Board is of the view that it should not consider any such arrangements untilafter completion of all the existing trials. At that time the Company will be ina better position to determine the most commercially advantageous routes tomarket for this product. PHC is currently reviewing various options for the development andcommercialisation of Myconate, which, it believes, will have applications acrossa wide range of the world's most valuable crops and agricultural plants, inparticular maize and soybean, the two highest value row crops in the world. PHC expects to release its full year results early March 2006 and it will thenprovide a further update on the status of the ongoing Myconate trials. For further information please contact: John Brady Jeremy Carey / Christian Taylor-WilkinsonPlant Health Care Tavistock CommunicationsTel: 020 7920 3150 (on 25/26 January) Tel: 020 7920 3150Tel: 001 6035253702 (thereafter) This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.